4D Molecular Therapeutics
FDMT
77 hedge funds and large institutions have $542M invested in 4D Molecular Therapeutics in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 43 increasing their positions, 7 reducing their positions, and 8 closing their positions.
514% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 7
175% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 8
22% more funds holding
Funds holding: 63 → 77 (+14)
5.87% more ownership
Funds ownership: 71% → 76.86% (+5.9%)
5% more capital invested
Capital invested by funds: $515M → $542M (+$26.7M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
98% less call options, than puts
Call options by funds: $9K | Put options by funds: $495K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$23M |
| 2 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$18.8M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
+$17.6M |
| 4 |
BlackRock
New York
|
+$15.9M |
| 5 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
-$16.2M |
| 2 |
CC
Casdin Capital
New York
|
-$13.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$10.1M |
| 4 |
CC
Centiva Capital
New York
|
-$7.22M |
| 5 |
Millennium Management
New York
|
-$4.19M |
FDMT Hedge Fund Activity: Q4 2021 in Review
77 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q4 2021, worth a combined $542M — up 5.2% from $515M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new FDMT positions and 8 closed out — a net gain of 14 holders — while 43 added to existing stakes and 7 trimmed.
The largest buyer was State Street, adding an estimated $23M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $16.2M sold.
- 77 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q4 2021, up from 63 in Q3 2021.
- Funds reported $542M of 4D Molecular Therapeutics stock for Q4 2021, up 5.2% quarter-over-quarter.
- 22 funds opened new 4D Molecular Therapeutics positions in Q4 2021 and 8 closed out, a net change of +14 holders.
- The largest 4D Molecular Therapeutics buyer in Q4 2021 was State Street, an estimated $23M added.
- The largest 4D Molecular Therapeutics seller in Q4 2021 was Alkeon Capital Management, an estimated $16.2M sold.
Based on aggregated 13F filings for Q4 2021.